Anti–myelin‐associated glycoprotein neuropathy: Where do we stand?
Open Access
- 21 August 2023
- journal article
- review article
- Published by Wiley in Muscle & Nerve
- Vol. 68 (6) , 823-832
Abstract
Myelin‐associated glycoprotein (MAG) is a transmembrane glycoprotein concentrated in periaxonal Schwann cell and oligodendroglial membranes of myelin sheaths that serves as an antigen for immunoglobulin M (IgM) monoclonal antibodies. Individuals who harbor anti‐MAG antibodies classically develop a progressive autoimmune peripheral neuropathy characterized clinically by ataxia, distal sensory loss, and gait instability, and electrophysiologically by distally accentuated conduction velocity slowing. Although off‐label immunotherapy is common, there are currently no proven effective disease‐modifying therapeutics, and most patients experience slow accumulation of disability over years and decades. The typically slowly progressive nature of this neuropathy presents unique challenges when trying to find effective anti‐MAG therapeutic agents. Drug development has also been hampered by the lack of validated outcome measures that can detect clinically meaningful changes in a reasonable amount of time as well as by the lack of disease activity biomarkers. In this invited review, we provide an update on the state of clinicometric outcome measures and disease activity biomarkers in anti‐MAG neuropathy. We highlight the insensitivity of widely used existing clinicometric outcome measures such as the Inflammatory Neuropathy Cause and Treatment (INCAT) disability score as well as the INCAT sensory subscore in anti‐MAG neuropathy, referencing the two previous negative randomized controlled clinical trials evaluating rituximab. We then discuss newly emerging candidate therapeutic agents, including tyrosine kinase inhibitors and enhanced B‐cell–depleting agents, among others. We conclude with a practical approach to the evaluation and management of anti‐MAG neuropathy patients.Keywords
This publication has 58 references indexed in Scilit:
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicityBlood, 2010
- Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathyNeurology, 2009
- Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathyAnnals of Neurology, 2009
- B cells as therapeutic targets in autoimmune neurological disordersNature Clinical Practice Neurology, 2008
- Predictors of response to rituximab in patients with neuropathy and anti–myelin associated glycoprotein immunoglobulin MJournal of the Peripheral Nervous System, 2007
- Terminal latency index in neuropathy with antibodies against myelin‐associated glycoproteinsMuscle & Nerve, 2007
- Antiglycolipid Antibodies in Motor NeuropathiesaAnnals of the New York Academy of Sciences, 1998
- Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM anti‐myelin‐associated glycoproteinAnnals of Neurology, 1993
- Complement-Mediated Demyelination in Patients with IgM Monoclonal Gammopathy and PolyneuropathyNew England Journal of Medicine, 1990
- Demyelination induced by intraneural injection of human antimyelin‐associated glycoprotein antibodiesMuscle & Nerve, 1988